PureTech Health's latest financial report reveals some key financial dynamics and company development trends. First, the company has nearly $320 million in cash reserves in the first half of 2025, while operating expenses have decreased from $66.7 million in the same period last year to $50 million. Management also highlighted three core spin-off entities: Seaport Therapeutics, Gallop Oncology, and Celea Therapeutics. Particularly noteworthy is that Seaport Therapeutics completed a $7.33 billion Series B financing, which also indicates the company's market recognition and growth potential.

Seaport Therapeutics focuses on the development of novel neuropsychiatric drugs, utilizing the Glyph platform for oral drug delivery. This platform was initially developed by PureTech Health and is part of its technological achievements. As of August 2025, the company holds a 35.1% stake in Seaport Therapeutics and enjoys tiered royalties (3%-5%) on drug sales. This further enhances the financial transparency of PureTech Health, providing investors with more basis to measure the realization of the company's value and highlighting the management's ability to successfully transfer assets outside the company's balance sheet.

Speaking of Cobenfy (KarXT), this drug originated from PureTech Health and is currently licensed and sold by another large pharmaceutical company. According to external analysts' sales forecasts, this drug could bring in $300 million in milestone and royalty payments for the company before 2033. This royalty stream is based on annual sales exceeding $2 billion, with a greater possibility of regulatory approvals, such as the upcoming data on Alzheimer's disease psychosis.

As for future plans, Celea Therapeutics' Deupirfenidone is expected to hold a Phase II meeting in the third quarter of 2025, with the goal of initiating Phase III in the first half of 2026. Meanwhile, Gallop Oncology anticipates obtaining preliminary efficacy results from its acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) studies in the fourth quarter of 2025, with more updates on survival rates and efficacy expected in the first half of 2026. The short-term milestones for Seaport Therapeutics have not been disclosed, but with the $325 million funding secured as of August 2025, plans remain robust.

Management expects that the company's cash flow will be further extended with external financing from Celea Therapeutics and Gallop Oncology. PureTech Health is working to further optimize its financial flexibility in R&D and operations through spin-offs and structural adjustments. These efforts are seen as key to sustaining the company's cash flow, which is expected to extend to 2028. This financial strategy reduces the risk of future dilution, allowing it to focus on the development of core innovation areas.